拉尼兰诺治疗代谢功能障碍相关脂肪性肝炎的机制与临床研究进展

摘要/Abstract

摘要： 代谢功能障碍相关脂肪性肝病(MASLD)是以胰岛素抵抗、脂质代谢紊乱和慢性炎症为特征的常见代谢性肝病,易进展为代谢功能障碍相关脂肪性肝炎(MASH)及肝纤维化。过氧化物酶体增殖物激活受体(PPAR)在调控脂质代谢、炎症反应与纤维化过程中发挥关键作用,成为MASLD治疗的潜在靶点。拉尼兰诺作为一类三重PPAR激动剂,能协同激活PPARα、PPARβ/δ及PPARγ,在Ⅱ期临床试验中已表现出良好疗效与安全性。本文系统回顾MASLD的发病机制与PPAR通路的多重生物学功能,重点聚焦拉尼兰诺的作用机制与研究进展,旨在为其后续临床试验设计与靶向治疗策略提供理论依据。

庄启程, 杨长青. 拉尼兰诺治疗代谢功能障碍相关脂肪性肝炎的机制与临床研究进展[J]. 肝脏, 2025, 30(8): 1036-1038.

/ 推荐

参考文献

[1] Younossi Z M, Koenig A B, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes [J]. Hepatology, 2016,64(1):73-84.
[2] Ran S, Zhang J, Tian F, et al. Association of metabolic signatures of air pollution with MASLD: observational and mendelian randomization study [J]. J Hepatol, 2025,82(4):560-570.
[3] Portincasa P, Khalil M, Mahdi L, et al. Metabolic dysfunction-associated steatotic liver disease: from pathogenesis to current therapeutic options [J]. Int J Mol Sci,2024,25(11):5640.
[4] Lefebvre P, Chinetti G, Fruchart J C,et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis [J]. J Clin Invest,2006,116(3):571-580.
[5] Carli F, Della Pepa G, Sabatini S, et al. Lipid metabolism in MASLD and MASH: from mechanism to the clinic [J]. JHEP Rep,2024,6(12):101185.
[6] Tacke F, Puengel T, Loomba R, et al. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH [J]. J Hepatol,2023,79(2):552-566.
[7] Esler W P, Cohen D E. Pharmacologic inhibition of lipogenesis for the treatment of NAFLD [J]. J Hepatol,2024,80(2):362-377.
[8] Zhao L, Zhang C, Luo X, et al. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis[J]. J Hepatol,2018,69(3):705-717.
[9] Pohl J, Ring A, Hermann T,et al. Role of FATP in parenchymal cell fatty acid uptake[J]. Biochim Biophys Acta,2004,1686(1-2):1-6.
[10] Fromenty B, Roden M. Mitochondrial alterations in fatty liver diseases[J]. J Hepatol, 2023,78(2):415-429.
[11] Francque S, Verrijken A, Caron S, et al. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis[J]. J Hepatol, 2015,63(1):164-173.
[12] Gastaldelli A, Casolaro A, Ciociaro D, et al. Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients[J]. Am J Physiol Endocrinol Metab,2009,297(1):E225-E230.
[13] Ricote M, Glass C K. PPARs and molecular mechanisms of transrepression[J]. Biochim Biophys Acta,2007,1771(8):926-935.
[14] Lanthier N, Molendi-Coste O, Horsmans Y,et al. Kupffer cell activation is a causal factor for hepatic insulin resistance[J]. Am J Physiol Gastrointest Liver Physiol,2010,298(1):G107-G116.
[15] Parlati L, Régnier M, Guillou H,et al. New targets for NAFLD[J]. JHEP Rep,2021,3(6):100346.
[16] Lefebvre P, Lalloyer F, Baugé E, et al. Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin[J]. JCI Insight, 2017,2(13):e92264.
[17] Sabatini S, Gastaldelli A. Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor[J]. J Hepatol,2025,82(6):950-952.
[18] Francque S M, Bedossa P, Ratziu V, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH[J]. N Engl J Med, 2021,385: 1547-1558.
[19] Barb D, Kalavalapalli S, Leiva E G, et al. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD[J]. J Hepatol, 2025,82:979-991.
[20] Balas B, Belfort R, Harrison S A, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis[J]. J Hepatol, 2007,47:565-570.